Joseph Allen, executive director of the Bayh-Dole Coalition, explains how molnupiravir, from Ridgeback Biotherapeutics, and partner Merck & Co. Inc., may have never had a chance to move out of the university onto pharmacy shelves without the government’s support.

Download transcript

The approval of antibody-drug conjugate Tivdak (tisotumab vedotin) for treating cervical cancer and the future of Genmab A/S are the subjects with the company's president and CEO, Jan van de Winkel.

Download transcript

An in-depth conversation with Lucio Rovati, CEO and chief scientific officer of Italy’s Rottapharm Biotech as they tackle the new world of DNA vaccines.

Download transcript

Laurie Halloran, president and CEO of Boston-based Halloran Consulting, shares her thoughts on the impact of COVID-19 on clinical trials.

Download transcript

Mark Goldsmith, Revolution Medicines Inc. president, CEO and chairman, talks about grappling with RAS mutations.

Download transcript

Howard Fillit, founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation, shares his insights on the impact of financial investments driving these therapies.

Download transcript

Biopharma deal-making activity, a closely watched marker of industry health, was alive and well in the second quarter. BioWorld Senior Analyst Karen Carey sifts through the numbers.

Download transcript